PETNET to make, distribute Lillys molecular imaging agent

PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, has entered into a commercial agreement with Eli Lilly that grants Siemens PETNET the right to manufacture and distribute Lilly’s molecular imaging agent that is currently under review by the FDA for PET imaging.

The Knoxville, Tenn.-based PETNET is the first company to sign an agreement for the commercial manufacturing and distribution of Lilly’s molecular imaging agent in the U.S., should it be FDA approved. Additionally, should Lilly’s molecular imaging agent be approved in markets outside the U.S., the companies said they would consider expanding this commercial agreement to those markets as well.


Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.